I. G. Ovsyannikova, N. Dhiman, R. M. Jacobson, R. A. Vierkant and G. A. Poland, “Frequency of Measles Virus-Specific CD4+ And CD8+ T Cells in Subjects Seronegative or Highly Seropositive for Measles Vaccine,” Clinical and Diagnostic Laboratory Immunology, Vol. 10, No. 3, 2003, pp. 411-416.

has been cited by the following article:

• TITLE: Evaluation of a Recombinant Measles Virus as the Expression Vector of Hepatitis C Virus Envelope Proteins

  AUTHORS: Yuri Kasama, Masaaki Satoh, Makoto Saito, Seiji Okada, Chieko Kai, Kyoko Tsukiyama-Kohara

  KEYWORDS: MV, HCV, E1, E2, Human PBMC, NOD/Scid/Jak3null Mouse

  JOURNAL NAME: World Journal of Vaccines, Vol.1 No.3, August 24, 2011

  ABSTRACT: Measles virus (MV) is a negative strand RNA virus of the family Paramyxoviridae, and the attenuated Edmonston-B strain can be engineered by the reverse genetics system. Here we constructed the recombinant Edmonston strain of measles virus (MV-Ed) that expressed hepatitis C virus (HCV) envelope proteins (rMV-E1E2). The rMV-E1E2 successfully expressed HCV E1 and E2 proteins. To evaluate its immunogenicity, NOD/Scid/Jak3null mice that were engrafted with human peripheral blood mononuclear cells (huPBMC-NOJ) were infected with this rMV-E1E2. Although human lymphocytes could be isolated from the spleens of mock-infected mice during the 2-weeks-long experiment, the proportion of mice that were infected with MV or rMV-E1E2 was decreased in a viral dose-dependent manner. Over 103 PFU of virus infection decreased the human PBL to less than 5%. Significant decrease of B cell population in human PBL from rMV-E1E2 infected NOD-SCID mice and decrease of T cell population in those from MV infected mice were observed. Human antibody production in these mice was also examined. Thus, the results in this study may contribute for future improvement of recombinant vaccine using measles virus vector.